PreSize® Neurovascular Landmark Clinical Impact Trial Receives ESMINT Endorsement
London, 9th July 2025 - Oxford Heartbeat is excited to share that the clinical impact trial of its decision-support software PreSize® Neurovascular has been endorsed by The European Society of Minimally Invasive Neurological Therapy (ESMINT). ESMINT endorsement signifies strong support from a leading authority in neurointerventional medicine, reinforcing Oxford Heartbeat’s mission to set a new standard of evidence generation for the use of decision-support software in neuroradiology.
This is yet another piece of fantastic news from the prospective, multi-centre trial, which aims to quantify the benefits of using PreSize in clinical practice. The trial is being independently run by Imperial Clinical Trials Unit (ICTU) and successfully completed patient recruitment of 103 participants last year, involving 9 UK hospitals and 22 interventional neuroradiologists. Funded by the UK’s National Institute for Health and Care Research’s (NIHR) prestigious AI in Health and Care Award and featured on BBC Click, this is the first trial of its kind for decision-support software in the neurovascular space.
The trial’s Chief Investigator, Professor Dr Tufail Patankar, from Barking, Havering and Redbridge University Hospitals NHS Trust, explained the significance of ESMINT endorsement, saying “ESMINT plays a crucial role in shaping clinical practice in neurointervention, so their endorsement of PreSize trial highlights the trial’s robust methodology, and validates its scientific and clinical relevance.”
The 103 patients included in the registered study were diagnosed with a cerebral aneurysm and scheduled to be treated minimally invasively. For each patient, their treatment was planned twice - both with and without PreSize - and information was collected on the accuracy of PreSize, surgical efficiency metrics, and patient outcomes. The results of the trial will be used to compare clinical decision making with traditional planning methods vs. with PreSize. The data is currently undergoing independent analysis by ICTU, and the results are anticipated to be published later this year.
Dr Katerina Spranger, the CEO and founder of Oxford Heartbeat said, “this trial is so exciting because it is the first in the field where the data is collected in a real-world prospective setting to demonstrate objective and measurable benefits that PreSize brings to patients and clinical teams.”
Publication of the trial results will position PreSize as the only software of its kind to have the highest Level 1 evidence, according to the American Journal of Neuroradiology (AJNR) guidelines. Therefore, the endorsed, prospective, clinical impact trial of PreSize will set a new standard for evidence generation regarding the use of decision-support software to support clinical decision making in neurovascular surgery and beyond.
Dr Patankar explained the impact going forward, adding that “ESMINT endorsement will increase the visibility of the trial across the European neurovascular community, opening the door for wider collaboration, support, and adoption of the technology in clinical practice.”
Note to editors
